Komori
General Meetings of Shareholders4521KAKEN PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Meeting Materials

The 106th Annual General Meeting of Shareholders will be held on 26 June 2026, with proposals concerning the appropriation of surplus, the election of directors and Audit & Supervisory Board members, and the payment of directors’ bonuses. All 8 directors are scheduled to be re-elected, while 1 of the 2 Audit & Supervisory Board members is scheduled to be newly elected.

Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (106th)
2026
Jun 26
Date and timeat 10:00 a.m. (registration opens at 9:00 a.m.)27 days from this disclosure to the meeting
Matters for resolution4 items
  1. Appropriation of surplus

  2. Election of 8 directors

  3. Election of 2 Audit & Supervisory Board Members

  4. Payment of directors’ bonuses

Company proposal only. The company states that there was no shareholder proposal.A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee
8Nominees
0New
3Outside
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (106th)
Date and timeFriday, 26 June 2026, at 10:00 a.m. (registration opens at 9:00 a.m.)
Matters for resolutionProposal 1: Appropriation of surplus, Proposal No. 2: Election of 8 directors, Proposal No. 3: Election of 2 Audit & Supervisory Board Members, Proposal No. 4: Payment of directors’ bonuses
Shareholder ProposalNone
Director nominee8, including 0 new candidates and 3 outside directors
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The director candidates are being elected upon the expiration of their terms, and the company considers them suitable based on their respective experience, knowledge and achievements. The Audit & Supervisory Board members are being elected following the expiration of 1 member’s term and the resignation of 1 member.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Meeting Materials | KAKEN PHARMACEUTICAL CO.,LTD. (4521) timely disclosure | Komori